
1151

1152



1153

Figure S1: Anti-apoptosis mediated by ADSC-NVs in vitro. (A) Viability of 1154 ADSC-NVs or ADSC-EVs treated HUVECs was measured by Annexin-V-1155 FITC/PI staining. We defined Annexin V+/PI- as early apoptotic stage, Annexin 1156 V+/PI+ as apoptotic cells, and Annexin V-/PI+ as dead cells. Total apoptotic rate 1157 was the sum of early apoptotic rate and apoptotic rate. (B, C) mRNA 1158 expressions of B-cell lymphoma-2 (Bcl-2) (B) and BCL2-associated X (Bax) (C) 1159 in HUVECs treated with ADSC-NVs or ADSC-EVs were analyzed using qRT-1160 PCR (n = 3 per group). (D) Protein levels of Bcl-2 and Bax in HUVECs after 1161 ADSC-NVs or ADSC-EVs stimulation. *p < 0.05, **p < 0.01, ***p < 0.001, 1162 ****p<0.0001. 1163